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USA300 is the dominant strain responsible for commu-
nity-associated (CA) methicillin-resistant Staphylococcus 
aureus (MRSA) infections in most of the United States. We 
examined isolates from outbreaks of MRSA skin infections 
in rural southwestern Alaska in 1996 and 2000 (retrospec-
tive collection) and from the hospital serving this region in 
2004–2006 (prospective collection). Among 36 retrospec-
tive collection isolates, 92% carried Panton-Valentine leuko-
cidin (PVL) genes; all carried staphylococcal chromosomal 
cassette mec (SCCmec) type IV. None belonged to clonal 
complex (CC) 8, the CC associated with USA300; 57% were 
sequence type (ST) 1, and 26% were ST30; 61% were clin-
damycin resistant. In the prospective collection, 42 isolates 
were PVL+ and carried SCCmec type IV; 83.3% were ST1, 
9.5% were ST30, and 7.1% were ST8. Among 120 prospec-
tive isolates, 57.5% were clindamycin resistant. CA-MRSA 
epidemiology in southwestern Alaska differs from that in the 
lower 48 states; ST8 strains were rarely identiﬁ  ed and clin-
damycin resistance was common.
S
taphylococcus aureus is a common cause of skin and 
soft tissue infections (SSTIs), endovascular infections, 
pneumonia, septic arthritis, endocarditis, osteomyelitis, for-
eign-body infections, and sepsis (1). In the United States, 
epidemic infection with community-associated (CA) meth-
icillin-resistant Staphylococcus aureus (MRSA) is occur-
ring, with many reports of MRSA infections among per-
sons without traditional healthcare-associated MRSA risk 
factors (2–4). As a result, the epidemiology of CA-MRSA 
has become complex (5).
Novel MRSA isolates that are less likely to be resis-
tant to antimicrobial drugs other than β-lactams have been 
identiﬁ  ed in association with epidemic CA-MRSA infec-
tions. These CA-MRSA strains are commonly susceptible 
to drugs such as clindamycin, gentamicin, tetracyclines, 
and rifampin. Moreover, the genes encoding the pore-form-
ing, bicomponent cytotoxin, Panton-Valentine leukocidin 
(PVL), are nearly universally present in novel CA-MRSA 
strains. However, evidence from animal studies has been 
contradictory in assessing the importance of PVL in the 
virulence of these isolates (6,7).
In addition to the PVL genes, strains that cause CA-
MRSA infections typically carry staphylococcal chromo-
somal cassette mec (SCCmec) types IV and V, small ge-
netic resistance elements that are presumably mobile. A 
single CA-MRSA genetic background, USA300 (deﬁ  ned 
by pulsed-ﬁ  eld gel electrophoresis), corresponding to se-
quence type (ST) 8 by multilocus sequence typing (MLST), 
has become predominant among CA-MRSA isolates in 
many centers in the United States (8–10). The reason for 
the dominance of USA300 is not clear.
Other MRSA strains that are broadly susceptible to 
non–β-lactams and have PVL genes and SCCmec IV or V 
have predominated among CA-MRSA strains collected in 
various regions of the world (11). In an area of rural Alaska, 
SSTIs caused by CA-MRSA isolates have been a public 
health concern since 1996 (12–14). We explored the molecu-
lar diversity of strains causing CA-MRSA in this region and 
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investigated the hypothesis that a transition to the dominance 
of USA300 had also occurred in this region, similar to that 
documented elsewhere in the United States (15).
Methods
The study was reviewed and approved by the Institu-
tional Review Boards of the Centers for Disease Control 
and Prevention (CDC) (Atlanta, GA, USA) and the Alaska 
Area Native Health Services. The study protocol and draft 
manuscript were reviewed and approved by the Yukon 
Kuskokwim Health Corporation (YKHC).
Two collections of MRSA isolates were available for 
study. They were obtained from the same region of south-
western Alaska. Southwestern Alaska is a roadless area 
populated principally by Alaska Natives, the descendants 
of the indigenous people of Alaska. The regional commer-
cial center is Bethel (population 5,700), which is served 
by the 50-bed Yukon Kuskokwim Delta Regional Hospital 
(YKDRH) (13,14). This hospital is the only one serving 
the 25,000 persons in the YKHC, which is a tribal health 
corporation that operates a comprehensive system of care 
in the region for Alaska Natives, including hospital and 
village-based clinics. Most residents have a subsistence 
lifestyle, and many homes lack running water. Primary 
healthcare delivery occurs at village health clinics staffed 
by community health aides who provide acute and preven-
tive services. Travel between villages is principally by air-
plane, boat, or snowmobile; no roads connect these regions 
to the rest of Alaska. The clinical microbiology laboratory 
at YKDRH serves the hospital and all outpatient clinics in 
the surrounding region.
Retrospective Collection
This collection included 36 MRSA strains randomly 
selected from those obtained during 2 SSTI outbreaks. The 
1996 outbreak occurred in 1 village (12). In the second out-
break in 2000, MRSA isolates were collected from infec-
tions, usually SSTIs, among residents of 29 villages, from 
wooden surfaces of steam baths in 1 village and from cul-
tures obtained to assess nasal colonization (14).
Prospective Collection
We conducted laboratory-based surveillance for 
MRSA from January 2004 through January 2006 at the 
YKDRH in Bethel. During the study period, 85% of all S. 
aureus isolates at YKDRH were identiﬁ  ed as MRSA (L. 
Pruitt, pers. comm., January 2008). The ﬁ  rst 5 unique-
patient MRSA isolates each month were collected by the 
YKDRH laboratory and sent to the Arctic Investigations 
Program at CDC for storage and processing. Information 
accompanying each isolate included basic demographics, 
location of clinical services, and date and anatomic site of 
isolation. Isolates were identiﬁ  ed at the YKDRH clinical 
microbiology laboratory. Antimicrobial drug susceptibili-
ties were determined by the Vitek automated system (bio-
Mérieux Vitek, Inc., Durham, NC, USA) at the University 
of Chicago. Isolates were stratiﬁ  ed by patient age and clin-
damycin susceptibility. Age strata were then compared for 
differences in the percentage of isolates susceptible to clin-
damycin by χ2 test using Stata SE version 9.2 (StataCorp, 
College Station, TX, USA).
Genetic Testing
MLST was performed as described (16) at the Univer-
sity of Chicago. Sequence types were grouped into clonal 
complexes (CCs) when they were genetically related; 
e.g., ST8 belongs to CC8. CCs were assigned by using 
the eBURST algorithm as described (17). The presence of 
mecA was assessed and the SCCmec type of each strain 
was determined by using criteria previously described (18). 
Presence of lukF-PV and lukS-PV encoding the PVL toxin 
was assessed by PCR as described (19). Isolates that had 
these genes were PVL+.
Results
Thirty-six isolates were available from the retrospec-
tive collection. Six were from the 1996 investigation out-
break collected from January 6, 1997, through January 6, 
1998, and 30 from the 2000 outbreak collected from April 
17, 2000, through September 20, 2000. Of the 2000 out-
break isolates, 3 were collected from steam bath bench sur-
faces, 12 from nasal survey cultures, and 15 from material 
obtained from SSTIs. Of 36 isolates in the retrospective 
collection, 33 (92%) were PVL+ (14).
SCCmec and MLST typing were performed on the ret-
rospective collection isolates. All carried SCCmec type IV. 
ST1 was the most common MLST genotype, accounting 
for 20 (57%) of 36 isolates; ST30 accounted for 9 (26%) 
of 36 and ST59 for 1 (2.8%) of 36. When isolates were 
grouped in clonal complexes, 22 (63%) belonged to CC1, 
11 (32%) to CC30, and 2 (6%) to CC59. None were ST8 
or belonged to CC8, the CC most closely associated with 
USA300 (Table 1).
Only 14 (39%) of 36 MRSA retrospective collection 
isolates were susceptible to clindamycin when clindamy-
cin single-agent testing and D-test results were taken into 
account; 31% were susceptible to erythromycin. Suscepti-
bility to gentamicin, ciproﬂ  oxacin, rifampin, vancomycin, 
and trimethoprim-sulfamethoxazole was nearly universal 
(Table 1).
Of the 120 MRSA patient isolates available from the 
prospective collection, 117 were from patients whose sex 
was known; 61 (50.8%) were from males. Most patients 
were 13–49 years of age. Among patients with known ven-
ue of care, 106 (90.6%) of 117 were outpatients, 59 (50.4%) 
of whom received care in the emergency department. All 
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but 1 of the 11 inpatients had their isolate obtained within 
72 hours of admission, i.e., their infections had onset in the 
community. Most (90.0%) isolates were from material ob-
tained from SSTIs. Other sites of isolation included blood, 
urine, respiratory tract, and bone (Table 2).
A random sample of one third of the prospective col-
lection isolates (42/120) spanning the entire collection 
interval were assayed for PVL toxin genes, SCCmec, and 
MLST type. All 42 isolates tested were PVL+, and all car-
ried the SCCmec type IV element. Most MRSA isolates in 
the prospective collection were ST1 (35/42, 83.3%), which 
likely represent USA400. Other types included ST30 (4/42, 
9.5%) and ST8 (3/42, 7.1%). ST8 isolates likely represent 
USA300 (Table 1).
Antimicrobial drug susceptibility data were available 
for all 120 isolates in the prospective collection; 51 (42.5%) 
of 120 were susceptible to erythromycin and clindamycin. 
There was no discordance in erythromycin and clindamy-
cin susceptibility; therefore, no isolate underwent the D-
zone test. Nearly all isolates in the prospective collection 
were susceptible to ciproﬂ   oxacin (93.3%), gentamicin 
(95.8%), and rifampin (97.5%). All isolates were suscep-
tible to trimethoprim-sulfamethoxazole and vancomycin. 
More than half (57.5%) of the isolates were resistant to >2 
classes of non–β-lactam antimicrobial drugs; most of these 
were accounted for by isolates resistant to erythromycin 
and clindamycin (Table 1).
We examined the susceptibility to clindamycin of 
MRSA isolates from the prospective collection stratiﬁ  ed by 
patient age groups (0–2, 3–12, 13–20, 21–49, >50 years of 
age). There were no signiﬁ  cant differences or trends in the 
rate of clindamycin resistance among different age strata 
(p = 0.47).
Discussion
CA-MRSA isolates from southwestern rural Alaska 
differed in important ways from isolates collected in other 
parts of the United States. These isolates almost universal-
ly belonged to CC1, with a minor representation in CC30, 
CC59, and CC8. Elsewhere in the United States, USA300 
(belonging to CC8) has become the most common cause of 
community-associated SSTIs at medical centers in Atlanta, 
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Table 1. Selected characteristics of MRSA isolates from southwestern Alaska, 1997, 2000, and 2004–2006* 
Characteristic  Retrospective collection, no. (%) Prospective collection, no. (%) 
Drug susceptibility  n = 36   n = 120 
  Ciprofloxacin  36 (100)  112 (93.3) 
  Clindamycin, total†  14 (39)  51 (42.5) 
    Single-agent testing  33 (92)  51 (42.5) 
  D-test  negative  3/22  (14)  NA 
  Erythromycin  11 (31)  48 (40.0) 
  Gentamicin  35 (97)  115 (95.8) 
  Rifampin  36 (100)  117 (97.5) 
  Vancomycin  36 (100)  120 (100) 
  Trimethoprim-sulfamethoxazole  35 (97)  120 (100) 
Resistance to >2 non–ȕ-lactam antimicrobial drug classes  21 (58)  69 (58) 
PVL genes present  n = 36  n = 42 
  Yes  33 (92)  42 (100) 
 No  3 (8)  0 
SCCmec type IV  36 (100)  42 (100) 
MLST CC type     
  CC1  22 (63)  35 (83) 
  ST1  20  (57)  35  (83) 
  ST1slv‡  1  (3)  0 
  ST474  1  (3)  0 
 CC8  0 3  (7) 
  ST8  0  3  (7) 
  CC30  11 (32)  4 (10) 
  ST30  9  (26)  4  (10) 
  ST484  1  (3)  0 
  ST535  1  (3)  0 
 CC59  2  (6)  0 
  ST59  1  (3)  0 
  ST59slv‡  1  (3)  0 
*MRSA, methicillin-resistant Staphylococcus aureus; NA, not applicable; PVL, Panton-Valentine leukocidin; SCCmec, staphylococcal chromosomal 
cassette mec; MLST, multilocus sequence typing; CC, clonal complex; ST, sequence type. 
†Indicates clindamycin susceptibility by single-agent testing and negative D-test results. D-tests for inducible clindamycin resistance were not indicated for 
any isolates from the prospective collection and were performed for 22 isolates in the retrospective collection. 
‡slv, single-locus variant by MLST testing. RESEARCH
Baltimore, San Francisco, Houston, Chicago, and Los An-
geles (2–4,8,9) and among adults with SSTIs who came to 
emergency departments in 17 cities (8). In contrast, ST8 
(corresponding to USA300) was an infrequent genotype 
among MRSA isolates from rural Alaska in 2004–2006 
and was absent among isolates from 2 outbreaks in sepa-
rate villages in 1996 and 2000. Despite these differences in 
genetic background among the CA-MRSA isolates, nearly 
all isolates tested were PVL+ and all carried SCCmec IV.
The molecular epidemiology of CA-MRSA infection 
in Alaska underscores the worldwide geographic diversity 
of novel CA-MRSA genetic backgrounds identiﬁ  ed in the 
past decade. Isolates containing the PVL genes and either 
SCCmec IV or SCCmec V that lack resistance to most 
non–β-lactam antimicrobial drugs have been identiﬁ  ed in 
6 continents. Examples include ST5 in France and Swit-
zerland; ST80 in Belgium, Croatia, Denmark, England, 
Finland, Germany, Greece, the Netherlands, Norway, Ro-
mania, Scotland, Slovenia, and Sweden; and ST22 in Ger-
many and the Netherlands (11).
The 3 most common genetic background types in rural 
Alaska (ST1, ST59, and ST30) have been reported from 
studies of MRSA in communities elsewhere. ST1, corre-
sponding to pulsed-ﬁ  eld gel electrophoresis type USA400, 
was the strain type responsible for the deaths of 4 children 
reported in the midwestern United States (20) and the type 
that predominated in Chicago (10) and other regions in the 
late 1990s. The prototype strain is MW2, the genome of 
which has been sequenced (21). ST1 has become a rare 
cause of SSTIs in Chicago, Texas, and California, and 
among SSTI patients at emergency departments in 17 US 
cities (8,10).
In Taiwan, ST59 is predominant among strains that are 
PVL+ and carry SCCmec IV or VT (18). USA1000, which 
is also an ST59 strain, circulates among persons with no 
known exposure to the healthcare system (22). Some genet-
ic diversity has been noted among ST59 strains as shown 
by variation in staphylococcal protein A (spa) typing 
(11,23–25). ST59 strains were also isolated at a decreasing 
frequency in 1997–2001 from patients in a California jail 
(15), and in Western Europe and Singapore (11). We found 
1 ST59 isolate and 1 single-locus variant of ST59 in the 
retrospective collection from the 1996 and 2000 outbreaks 
but found none in the prospective collection.
The evolutionary history of ST30 MRSA strains is 
complex; the acquisition of the SCCmec element and the 
PVL genes has likely occurred in this genetic background 
on several occasions. Phage type 80/81 strains of S. aureus, 
virulent nosocomial pathogens in the 1950s and 1960s, 
shared this ST background (26). By examining the pattern 
of resistance-gene carriage in various MRSA genetic back-
grounds, Diep et al. proposed an evolutionary relationship 
among ST30 strains, suggesting that an MSSA ST30 strain 
sequentially added to its genome phage-encoded PVL toxin 
genes and the SCCmec IV element (27). However, a strain 
of ST30 MRSA isolated in 1991 from Wisconsin lacked 
the PVL genes but carried SCCmec IV (25), which suggest-
ed that the sequence of events hypothesized by Diep et al. 
does not universally describe the evolution of these strains 
(27). Among 5 ST30 MRSA isolates collected in Japan in 
1979–1985, 3 were PVL+ and all carried the SCCmec type 
I element (28). ST30 isolates reported from various regions 
commonly carry PVL genes and the SCCmec IV element 
but can differ in spa type, which suggests a continued and 
complex evolutionary trajectory for this prevalent sequence 
type (8,11,18,24,29–32).
The difference in PVL+, SCCmec IV strain types of 
MRSA in rural Alaska compared with those in the lower 
48 states suggests that Alaska may represent an earlier part 
of the epidemic curve of CA-MRSA. For example, there 
was a shift from USA400 to USA300 as the predominant 
clindamycin-susceptible, PVL+, SCCmec IV-containing 
MRSA strain in Chicago after 2000 (10). The predomi-
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Table 2. Demographic and clinical characteristics for 120 patients 
infected with MRSA isolates in the prospective collection, 
southwestern Alaska, 2004–2006* 
Characteristic   No. (%) 
Sex 
 Male  61  (50.8) 
 Female  56  (46.7) 
 Unknown  3  (2.5) 
Age, y 
 >1–2  11  (9.2) 
 3–12  14  (11.7) 
 13–20  22  (18.3) 
 21–49  53  (44.2) 
>50 18 (15.0) 
 Unknown  2  (0.2) 
Location of care 
 Inpatient  11  (9.2) 
 Outpatient  106  (88.4) 
Emergency department  59 (49.2) 
Other outpatient  47 (39.2) 
 Unknown  3  (2.5) 
Place of onset by 72-h rule† 
 Community  114  (95.0) 
 Hospital  1  (0.8) 
 Unknown  5  (3.3) 
Site of isolation 
 Blood  3  (2.5) 
  Respiratory tract  1 (0.8) 
 Skin/wound  108  (90.0) 
 Urine  2  (1.7) 
 Bone/joint  1  (0.8) 
 Other  5  (4.2) 
*MRSA, methicillin-resistant Staphylococcus aureus.
†MRSA isolates were considered community onset if they were obtained 
from a patient in the outpatient setting or from a hospitalized patient within 
72 h of admission; only 1 isolate was obtained from a patient who was 
considered to have had onset of the infection in the hospital. MRSA, Rural Southwestern Alaska
nance of ST1 strains in southwestern Alaska may reﬂ  ect 
geographic isolation of this region or improved ﬁ  tness of 
the strain in the rural Alaskan environment. The clinical 
spectrum of these community-onset cases is similar to 
MRSA disease elsewhere with a predominance of SSTIs 
and few associated instances of bacteremia or other inva-
sive illnesses. This disease spectrum is also similar to that 
of earlier reports of infections caused by MRSA from this 
region (13,14). O’Hara et al., using phylogenetic analyses 
of the lukSF-PV sequences coding PVL toxin in a sample of 
international clinical MRSA isolates, recently hypothesized 
that USA300 emerged after a CC8 MRSA strain acquired 
the PVL genes from the preexisting, virulent MW2 strain 
(33). If this event was the genesis of USA300, this event 
may have occurred in the lower 48 states, and USA300 had 
not spread to southwestern Alaska, where USA400 strains 
still predominated in early 2006.
All MRSA isolates we tested carried SCCmec type IV. 
So-called healthcare-associated MRSA isolates typically 
carry SCCmec types II or III, lack PVL genes, tend to be 
resistant to a greater number of non–β-lactam antimicro-
bial drugs, and were predominant among strains isolated 
from cases of hospital infections in the United States before 
2000 (5). Such healthcare-associated MRSA isolates were 
absent from our isolate collections, even from the prospec-
tive collection, which was a random sample of MRSA iso-
lates that included inpatients in the region served by the 
hospital laboratory for 2 years. In contrast, at the University 
of Chicago in 2004–2005, 8.6% of MRSA isolates from 
pediatric infections and 51.7% from adult infections car-
ried SCCmec II (5).
The PVL+, SCCmec IV–bearing strains of MRSA from 
Alaska that we studied showed a high percentage of clin-
damycin resistance (57.5%). In contrast, strains of MRSA 
that cause community-onset skin infections elsewhere in 
the United States are commonly susceptible to clindamycin 
(2–4,8), although exceptions have been documented (34), 
most recently in San Francisco among men who have sex 
with men infected by USA300 strains (35). Isolates from 
Alaska also had a relatively low percentage of erythromy-
cin resistance, which reﬂ  ects the predominance of the ST1 
background. Erythromycin-resistant MRSA strains likely 
have the erm gene, which confers inducible or constitutive 
resistance to clindamycin, although there are other molecu-
lar mechanisms for clindamycin resistance. Surprisingly, 
among the prospective isolate collection, every isolate re-
sistant to erythromycin was also resistant to clindamycin 
by single-agent testing, an observation suggesting that the 
presumably erm-mediated phenotype became constitutive 
more often. Compared with antimicrobial drug susceptibil-
ities among MRSA identiﬁ  ed in Alaska in 2000, clindamy-
cin resistance remained high but decreased slightly from 
61% to 57.5%, ciproﬂ  oxacin resistance increased from 0% 
to 7%, and susceptibilities to other antimicrobial drugs re-
mained similar in the prospective collection. In contrast 
to the situation elsewhere in much of the United States, in 
southwestern Alaska, clindamycin should be avoided as a 
ﬁ  rst-line agent for treatment of community-onset SSTIs.
Our study was limited because the isolates we exam-
ined were from patients in 1 region and the number avail-
able in the retrospective collection was not large. The 
prospective collection was obtained from 1 clinic system 
and its community hospital, which may not be representa-
tive of other regions of Alaska. Furthermore, few clinical 
data were available regarding patients from whom these 
isolates were obtained. Our data suggest that further re-
search is needed to clarify the enigma of nearly simultane-
ous emergence and high prevalence of MRSA strains with 
PVL toxin genes and SCCmec type IV elements in different 
predominant genotype backgrounds in different regions of 
the world.
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